{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:50:39Z","timestamp":1764510639108},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13000-019-0804-6","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T19:11:41Z","timestamp":1553800301000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass"],"prefix":"10.1186","volume":"14","author":[{"given":"Haiyan","family":"Bao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juehua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica K.","family":"Altman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Frankfurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda L.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"804_CR1","unstructured":"Pileri SA, Orazi A, Falini B. Myeloid Sarcoma. Swerdlow S, Campo E, Harris NL, Jaffe E, Pileri S, Stein S, Thiele, Arber D, Hasserjian R, Le Beau M, Orazi A, Siebert R, editor. WHO classification of Tumours of Haematopoietic and lymphoid tissues. Revised 4th edition ed. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 167."},{"issue":"11","key":"804_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/PAS.0000000000000727","volume":"40","author":"K Kawamoto","year":"2016","unstructured":"Kawamoto K, Miyoshi H, Yoshida N, Takizawa J, Sone H, Ohshima K. Clinicopathological, cytogenetic, and prognostic analysis of 131 myeloid sarcoma patients. Am J Surg Pathol. 2016;40(11):1473\u201383.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"804_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.blre.2016.04.001","volume":"30","author":"M Solh","year":"2016","unstructured":"Solh M, Solomon S, Morris L, Holland K, Bashey A. Extramedullary acute myelogenous leukemia. Blood Rev. 2016;30(5):333\u20139.","journal-title":"Blood Rev"},{"issue":"5","key":"804_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","volume":"17","author":"LM Almond","year":"2017","unstructured":"Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17(5):263\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"804_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/10245332.2017.1333275","volume":"23","author":"V Kaur","year":"2018","unstructured":"Kaur V, Swami A, Alapat D, Abdallah AO, Motwani P, Hutchins LF, et al. Clinical characteristics, molecular profile and outcomes of myeloid sarcoma: a single institution experience over 13 years. Hematology. 2018;23(1):17\u201324.","journal-title":"Hematology."},{"issue":"9","key":"804_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.prp.2016.06.014","volume":"212","author":"HQ Wang","year":"2016","unstructured":"Wang HQ, Li J. Clinicopathological features of myeloid sarcoma: report of 39 cases and literature review. Pathol Res Pract. 2016;212(9):817\u201324.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"804_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.leu.2404491","volume":"21","author":"SA Pileri","year":"2007","unstructured":"Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21(2):340\u201350.","journal-title":"Leukemia."},{"key":"804_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.anndiagpath.2017.10.004","volume":"32","author":"CM Magro","year":"2018","unstructured":"Magro CM, Kazi N, Sisinger AE. Primary cutaneous histiocytic sarcoma: a report of five cases with primary cutaneous involvement and review of the literature. Ann Diagn Pathol. 2018;32:56\u201362.","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"804_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2559.2002.01418.x","volume":"41","author":"SA Pileri","year":"2002","unstructured":"Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the international lymphoma study group based on 61 cases. Histopathology. 2002;41(1):1\u201329.","journal-title":"Histopathology."},{"issue":"14","key":"804_CR10","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1182\/blood-2011-04-347229","volume":"118","author":"RL Bakst","year":"2011","unstructured":"Bakst RL, Tallman MS, Douer D, Yahalom J. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785\u201393.","journal-title":"Blood."},{"issue":"2","key":"804_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/leu.2017.213","volume":"32","author":"C Meyer","year":"2018","unstructured":"Meyer C, Burmeister T, Groger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32(2):273\u201384.","journal-title":"Leukemia."},{"issue":"12","key":"804_CR12","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood.V96.12.3887","volume":"96","author":"JF DiMartino","year":"2000","unstructured":"DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, Cleary ML, et al. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 2000;96(12):3887\u201393.","journal-title":"Blood."},{"issue":"2","key":"804_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/10428194.2017.1339879","volume":"59","author":"K Kashofer","year":"2018","unstructured":"Kashofer K, Gornicec M, Lind K, Caraffini V, Schauer S, Beham-Schmid C, et al. Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing. Leuk Lymphoma. 2018;59(2):501\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"804_CR14","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.3324\/haematol.2017.179150","volume":"103","author":"S Voruz","year":"2018","unstructured":"Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, et al. Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma. Haematologica. 2018;103(1):e39\u201341.","journal-title":"Haematologica."},{"issue":"4","key":"804_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12185-010-0704-8","volume":"92","author":"E Hayase","year":"2010","unstructured":"Hayase E, Kurosawa M, Yonezumi M, Suzuki S, Suzuki H. Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18). Int J Hematol. 2010;92(4):659\u201363.","journal-title":"Int J Hematol"},{"issue":"11","key":"804_CR16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00277-018-3436-0","volume":"97","author":"A Tzankov","year":"2018","unstructured":"Tzankov A, Kremer M, Leguit R, Orazi A, van der Walt J, Gianelli U, et al. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th meeting of the European Association for Haematopathology (EAHP) organized by the European bone marrow working group, Basel 2016. Ann Hematol. 2018;97(11):2117\u201328.","journal-title":"Ann Hematol"},{"issue":"2","key":"804_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00428-016-1965-2","volume":"469","author":"Q Liu","year":"2016","unstructured":"Liu Q, Tomaszewicz K, Hutchinson L, Hornick JL, Woda B, Yu H. Somatic mutations in histiocytic sarcoma identified by next generation sequencing. Virchows Arch. 2016;469(2):233\u201341.","journal-title":"Virchows Arch"},{"issue":"4","key":"804_CR18","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MOH.0000000000000256","volume":"23","author":"BH Durham","year":"2016","unstructured":"Durham BH, Diamond EL, Abdel-Wahab O. Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol. 2016;23(4):416\u201325.","journal-title":"Curr Opin Hematol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-019-0804-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-019-0804-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:14:41Z","timestamp":1585268081000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-019-0804-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1186\/s13000-019-0804-6","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by institutional review board (IRB) of research under study STU00073565, Retrospective Study of Molecular Markers in Myeloid Neoplasms. Participate\u2019s consent is available upon request.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors are in agreement for the publication of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests except for Dr. Jessica K. Altman, who had the following disclosures: prIME Oncology, Speaker, 6\/1\/2018 Novartis Advisory Board, 6\/14\/2018 Cancer Expert Now Advisory Board, 6\/14\/2018 Agios Advisory Board, 12\/2\/2018 France Foundation Speaker, Data safety and monitoring, 1\/10\/2019 Glycomimetics, Committee Theradex, Advisory Board, 1\/11\/2019 AbbVie, Advisory Board, 2\/24\/2019.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}